Last reviewed · How we verify

Thyrogen + Radioiodine (131I) — Competitive Intelligence Brief

Thyrogen + Radioiodine (131I) (Thyrogen + Radioiodine (131I)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant hormone + radiopharmaceutical combination. Area: Oncology.

phase 3 Recombinant hormone + radiopharmaceutical combination TSH receptor (TSHR) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Thyrogen + Radioiodine (131I) (Thyrogen + Radioiodine (131I)) — Genzyme, a Sanofi Company. Thyrogen (recombinant human TSH) stimulates thyroid tissue to take up radioiodine (131I), enabling targeted destruction of thyroid cancer cells and metastases.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Thyrogen + Radioiodine (131I) TARGET Thyrogen + Radioiodine (131I) Genzyme, a Sanofi Company phase 3 Recombinant hormone + radiopharmaceutical combination TSH receptor (TSHR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant hormone + radiopharmaceutical combination class)

  1. Genzyme, a Sanofi Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Thyrogen + Radioiodine (131I) — Competitive Intelligence Brief. https://druglandscape.com/ci/thyrogen-radioiodine-131i. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: